绝经后激素治疗先前子痫前期妇女:芬兰全国队列研究。

IF 2.9 4区 医学 Q1 OBSTETRICS & GYNECOLOGY Climacteric Pub Date : 2023-12-01 Epub Date: 2023-07-21 DOI:10.1080/13697137.2023.2228687
M Venetkoski, O Ylikorkala, J M Joensuu, M Gissler, T S Mikkola, H Savolainen-Peltonen
{"title":"绝经后激素治疗先前子痫前期妇女:芬兰全国队列研究。","authors":"M Venetkoski, O Ylikorkala, J M Joensuu, M Gissler, T S Mikkola, H Savolainen-Peltonen","doi":"10.1080/13697137.2023.2228687","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>We compared the trends of hormone therapy (HT) use among women with and without a history of pre-eclampsia.</p><p><strong>Methods: </strong>This national cohort study consisted of women with a pre-eclamptic pregnancy (<i>n</i> = 31,688) or a normotensive pregnancy (<i>n</i> = 91,726) (controls) during 1969-1993. The data on their use of HT during 1994-2019 were traced from the National Medicine Reimbursement Register.</p><p><strong>Results: </strong>Both women with a history of pre-eclampsia and controls initiated HT at a mean age of 49.9 years. Cumulative HT™ use during the total follow-up did not differ between the groups (31.1% vs. 30.6%, <i>p</i> = 0.066). However, HT use in previously pre-eclamptic women was less common in 1994-2006 (20.2% vs. 22.4%, <i>p</i> < 0.001) and more common in 2007-2019 (22.1% vs. 21.1%, <i>p</i> < 0.001) than in controls. This trend was also seen in the annual changes of HT starters. Women with a history of pre-eclampsia used HT for a shorter time (6.3 vs. 7.1 years, <i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>In contrast to controls, HT use in previously pre-eclamptic women increased during the last half of the follow-up. This may reflect the changes in the international recommendations, the increased awareness of pre-eclampsia-related cardiovascular risk later in life and the aim to diminish this risk with HT.</p>","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Postmenopausal hormone therapy in prior pre-eclamptic women: a nationwide cohort study in Finland.\",\"authors\":\"M Venetkoski, O Ylikorkala, J M Joensuu, M Gissler, T S Mikkola, H Savolainen-Peltonen\",\"doi\":\"10.1080/13697137.2023.2228687\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>We compared the trends of hormone therapy (HT) use among women with and without a history of pre-eclampsia.</p><p><strong>Methods: </strong>This national cohort study consisted of women with a pre-eclamptic pregnancy (<i>n</i> = 31,688) or a normotensive pregnancy (<i>n</i> = 91,726) (controls) during 1969-1993. The data on their use of HT during 1994-2019 were traced from the National Medicine Reimbursement Register.</p><p><strong>Results: </strong>Both women with a history of pre-eclampsia and controls initiated HT at a mean age of 49.9 years. Cumulative HT™ use during the total follow-up did not differ between the groups (31.1% vs. 30.6%, <i>p</i> = 0.066). However, HT use in previously pre-eclamptic women was less common in 1994-2006 (20.2% vs. 22.4%, <i>p</i> < 0.001) and more common in 2007-2019 (22.1% vs. 21.1%, <i>p</i> < 0.001) than in controls. This trend was also seen in the annual changes of HT starters. Women with a history of pre-eclampsia used HT for a shorter time (6.3 vs. 7.1 years, <i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>In contrast to controls, HT use in previously pre-eclamptic women increased during the last half of the follow-up. This may reflect the changes in the international recommendations, the increased awareness of pre-eclampsia-related cardiovascular risk later in life and the aim to diminish this risk with HT.</p>\",\"PeriodicalId\":10213,\"journal\":{\"name\":\"Climacteric\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Climacteric\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/13697137.2023.2228687\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/7/21 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Climacteric","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13697137.2023.2228687","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/21 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:我们比较有和没有先兆子痫病史的妇女使用激素治疗(HT)的趋势。方法:这项国家队列研究包括1969-1993年间有子痫前期妊娠(n = 31688)或正常妊娠(n = 91726)的妇女(对照)。他们在1994-2019年期间使用HT的数据来自国家药品报销登记册。结果:两名有先兆子痫病史的女性和对照组开始HT的平均年龄为49.9岁。在总随访期间,两组之间的累计HT使用没有差异(31.1%对30.6%,p = 0.066)。然而,1994-2006年间,曾有子痫前期妇女使用激素的情况较少见(20.2%对22.4%,p p p)。结论:与对照组相比,曾有子痫前期妇女使用激素的情况在随访的后半段有所增加。这可能反映了国际建议的变化,对子痫前期相关心血管风险的认识的提高,以及通过HT降低这种风险的目的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Postmenopausal hormone therapy in prior pre-eclamptic women: a nationwide cohort study in Finland.

Objective: We compared the trends of hormone therapy (HT) use among women with and without a history of pre-eclampsia.

Methods: This national cohort study consisted of women with a pre-eclamptic pregnancy (n = 31,688) or a normotensive pregnancy (n = 91,726) (controls) during 1969-1993. The data on their use of HT during 1994-2019 were traced from the National Medicine Reimbursement Register.

Results: Both women with a history of pre-eclampsia and controls initiated HT at a mean age of 49.9 years. Cumulative HT™ use during the total follow-up did not differ between the groups (31.1% vs. 30.6%, p = 0.066). However, HT use in previously pre-eclamptic women was less common in 1994-2006 (20.2% vs. 22.4%, p < 0.001) and more common in 2007-2019 (22.1% vs. 21.1%, p < 0.001) than in controls. This trend was also seen in the annual changes of HT starters. Women with a history of pre-eclampsia used HT for a shorter time (6.3 vs. 7.1 years, p < 0.001).

Conclusions: In contrast to controls, HT use in previously pre-eclamptic women increased during the last half of the follow-up. This may reflect the changes in the international recommendations, the increased awareness of pre-eclampsia-related cardiovascular risk later in life and the aim to diminish this risk with HT.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Climacteric
Climacteric 医学-妇产科学
CiteScore
1.70
自引率
7.10%
发文量
53
审稿时长
1 months
期刊介绍: Climacteric is the official journal of the International Menopause Society (IMS). As an international peer-reviewed journal it publishes original research and reviews of all aspects of aging in women. Climacteric was founded by the IMS in 1998 and today has become a leading journal in the publication of peer-reviewed papers on the menopause, climacteric and mid-life health. Topics covered include endocrine changes, symptoms attributed to the menopause and their treatment, hormone replacement and alternative therapies, lifestyles, and the counselling and education of peri- and postmenopausal women. Climacteric, published bimonthly, also features regular invited reviews, editorials and commentaries on recent developments. The editorial review board of Climacteric includes leading scientific and clinical experts in the field of midlife medicine and research and is headed by its Editor-in-Chief, Professor Rod Baber of Australia. He and his team of Associate Editors act independently to set a clear editorial policy, co-ordinate peer review, and ensure a rapid response to submitted papers.
期刊最新文献
Statement of Retraction: Role of topical oxytocin in improving vaginal atrophy in postmenopausal women: a randomized, controlled trial Willingness to use clinical scales for menopause management among general practitioners. Isoflavones obtained from red clover improve both dyslipidemia and menopausal symptoms in menopausal women: a prospective randomized placebo-controlled trial. COVID-19 vaccination and postmenopausal bleeding: a retrospective cohort study. Mental health during the COVID-19 pandemic: the importance of social support in midlife women.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1